文献速递肝病消化道肿瘤与早癌

巢蛋白作为混合型肝细胞-胆管癌的诊断和预后标志物

Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
PubMed 文献 · J Hepatol · 2022-08-18

本研究在32个临床中心收集461例混合型肝细胞-胆管癌(cHCC-CCA)样本,以368例肝细胞癌(HCC)和221例肝内胆管癌(iCCA)为对照,评估巢蛋白免疫组化表达的诊断和预后价值。巢蛋白区分cHCC-CCA与HCC的AUC在手术和活检样本分别为0.85和0.86,区分cHCC-CCA与iCCA的AUC分别为0.59和0.60;巢蛋白高表达(>30%肿瘤细胞阳性)与手术切除和肝移植后更短的无病生存和总生存相关。

要点

  • 巢蛋白区分cHCC-CCA与HCC的AUC在手术样本为0.85、活检样本为0.86。
  • 巢蛋白区分cHCC-CCA与iCCA的AUC在手术样本为0.59、活检样本为0.60。
  • 巢蛋白高表达(>30%肿瘤细胞阳性)提示cHCC-CCA术后和移植后预后最差。

核心结论

  • 在不同临床场景中,巢蛋白具有诊断价值,并可用于识别预后最差的cHCC-CCA亚组。
  • 巢蛋白免疫组化可能用于细化风险分层并改善这一高度侵袭性恶性肿瘤患者的治疗分配。

研究设计与样本

  • 多中心系列研究,收集32个临床中心的461例cHCC-CCA样本,对照包括368例HCC和221例iCCA。
  • 在全肿瘤切片上进行巢蛋白免疫组化,采用受试者工作特征曲线和Cox回归模型评估诊断和预后性能。

主要发现

  • 巢蛋白区分cHCC-CCA与HCC的AUC在手术样本为0.85、活检样本为0.86。
  • 巢蛋白区分cHCC-CCA与iCCA的AUC在手术样本为0.59、活检样本为0.60。
  • 巢蛋白高表达(>30%肿瘤细胞阳性)的cHCC-CCA亚组在手术切除和肝移植后无病生存和总生存更短,活检评估时亦如此。

关键数值与推荐

  • 巢蛋白高表达定义为>30%肿瘤细胞阳性染色。
  • 巢蛋白区分cHCC-CCA与HCC的AUC在手术样本为0.85、活检样本为0.86。
  • 巢蛋白区分cHCC-CCA与iCCA的AUC在手术样本为0.59、活检样本为0.60。

临床怎么用

  • 巢蛋白免疫组化可能用于细化风险分层并改善cHCC-CCA患者的治疗分配。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver cancer (PLC) associated with a poor prognosis. Given the challenges in its identification and its clinical implications, biomarkers are critically needed. We aimed to investigate the diagnostic and prognostic value of the immunohistochemical expression of Nestin, a progenitor cell marker, in a large multicentric series of PLCs. METHODS: We collected 461 cHCC-CCA samples from 32 different clinical centers. Control cases included 368 hepatocellular carcinomas (HCCs) and 221 intrahepatic cholangiocarcinomas (iCCAs). Nestin immunohistochemistry was performed on whole tumor sections. Diagnostic and prognostic performances of Nestin expression were determined using receiver-operating characteristic curves and Cox regression modeling. RESULTS: Nestin was able to distinguish cHCC-CCA from HCC with AUCs of 0.85 and 0.86 on surgical and biopsy samples, respectively. Performance was lower for the distinction of cHCC-CCA from iCCA (AUCs of 0.59 and 0.60). Nestin, however, showed a high prognostic value, allowing identification of the subset of cHCC-CCA ("Nestin High", >30% neoplastic cells with positive staining) associated with the worst clinical outcome (shorter disease-free and overall survival) after surgical resection and liver transplantation, as well as when assessment was performed on biopsies. CONCLUSION: We show in different clinical settings that Nestin has diagnostic value and that it is a useful biomarker to identify the subset of cHCC-CCA associated with the worst clinical outcome. Nestin immunohistochemistry may be used to refine risk stratification and improve treatment allocation for patients with this highly aggressive malignancy. LAY SUMMARY: There are different types of primary liver cancers (i.e. cancers that originate in the liver). Accurately identifying a specific subtype of primary liver cancer (and determining its associated prognosis) is important as it can have a major impact on treatment allocation. Herein, we show that a protein called Nestin could be used to refine risk stratification and improve treatment allocation for patients with combined hepatocellular carcinoma, a rare but highly aggressive subtype of primary liver cancer.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Calderaro J, Di Tommaso L, Maillé P, et al. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma. J Hepatol. 2022. PMID: 35987274. doi:10.1016/j.jhep.2022.07.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。